Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
Authors:
- Michael J. WorleyMWMichael J. Worley
- Stephanie H. GusehSGStephanie H. Guseh
- J. Alejandro Rauh-HainJRJ. Alejandro Rauh-Hain
- Kristina A. WilliamsKWKristina A. Williams
- Michael G. MutoMMMichael G. Muto
- Colleen M. FeltmateCFColleen M. Feltmate
- Ross S. BerkowitzRBRoss S. Berkowitz
- Neil S. HorowitzNHNeil S. Horowitz
- 1 April 2013
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 129 (1) , 69-73
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Assessment of Risk Factors for 30-Day Hospital Readmission After Surgical Cytoreduction in Epithelial Ovarian CarcinomaInternational Journal of Gynecological Cancer, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Ovarian cancer: Survival and treatment differences by ageCancer, 2010
- Rehospitalizations among Patients in the Medicare Fee-for-Service ProgramNew England Journal of Medicine, 2009
- Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?Gynecologic Oncology, 2008
- Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survivalBritish Journal of Cancer, 2008
- Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patientsAmerican Journal of Obstetrics and Gynecology, 2005
- An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group studyGynecologic Oncology, 2004
- Morbidity of cytoreductive surgery in the elderlyAmerican Journal of Obstetrics and Gynecology, 2004
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsNew England Journal of Medicine, 1999